Stada evaluates a roughly €6 billion bid for French consumer‑health business Copper Consumer Health, signalling a major push into European OTC markets
Executive summary: Stada is examining a potential acquisition of French consumer‑health firm Copper Consumer Health for about six billion euros, according to a Handelsblatt report. The deal would markedly enlarge Stada’s OTC business, reshape the European consumer‑health landscape and likely attract antitrust review.
Who is involved: Stada (German generics manufacturer), Copper Consumer Health (French OTC pharmaceutical company), and relevant antitrust authorities in Germany, France and the EU.
Likely next: Stada may proceed with due diligence, file a formal offer, and seek clearance from competition regulators; if talks fail, the expansion plan could shift to other targets.
According to a media report cited by Handelsblatt, German generics maker Stada is examining the acquisition of Copper Consumer Health, a French over‑the‑counter pharmaceutical firm, for about six billion euros. Stada had previously announced an expansion strategy focused on consumer health assets. The deal, if completed, would reshape Stada’s portfolio and trigger antitrust scrutiny in both Germany and France. No official confirmation from either company has been issued yet.
Timeline
- — Pharma: Stada prüft wohl milliardenschweren Kauf von französischem Pharma-Unternehmen (Handelsblatt)
Analysis — what this means
Likely next events
- Stada confirms or denies the acquisition talks.
- Due diligence and valuation work are completed.
- Formal offer submitted and regulatory filings initiated in Germany, France and the EU.
Sectors affected
- Pharmaceuticals
- Consumer Health
- M&A in Europe
Regulatory implications
- EU merger control review under the EUMR
- French foreign investment screening (authority for foreign investments)
- German cartel office assessment
Historical parallels
- Sanofi’s 2018 acquisition of Bioverativ for €11.6 bn
- Takeda’s 2019 purchase of Shire for $62 bn
- Pfizer’s 2016 acquisition of Hospira for $17 bn
Key entities
Sources
Open the full interactive case file on Beyond →